Peptide Monograph

KPV

Lys-Pro-Val (C-terminal fragment of alpha-MSH)

At a Glance

Mechanism of Action

KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal amino acid residues 11–13 of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a tridecapeptide derived from proopiomelanocortin (POMC) that has well-established anti-inflammatory properties mediated primarily through melanocortin receptors (MC1R–MC5R).[1]

Critically, KPV retains the anti-inflammatory activity of alpha-MSH without activating melanocortin receptors. This dissociation of anti-inflammatory effects from receptor-mediated signaling is a key pharmacological feature. While the full alpha-MSH molecule requires MC1R binding for many of its effects, the KPV tripeptide appears to exert its anti-inflammatory action through a receptor-independent, intracellular mechanism.[1][2]

The primary mechanism involves direct inhibition of the NF-kB signaling pathway. KPV can penetrate cell membranes and enter the cytoplasm, where it interferes with the nuclear translocation of NF-kB, a master transcription factor that drives expression of pro-inflammatory cytokines. By suppressing NF-kB activation, KPV reduces production of pro-inflammatory mediators including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6).[2]

Brzoska, Luger, and colleagues demonstrated that KPV and other alpha-MSH C-terminal fragments inhibit NF-kB activation in human dermal fibroblasts and keratinocytes, reducing the inflammatory response to stimuli such as IL-1β and TNF-α. The anti-inflammatory effect was comparable to that of the full alpha-MSH molecule despite the absence of melanocortin receptor activation.[1][2]

KPV has generated particular interest for its potential role in gut inflammation. Preclinical studies have shown that KPV reduces intestinal inflammation in animal models of inflammatory bowel disease (IBD), promoting mucosal healing and reducing inflammatory infiltrate. The peptide's ability to penetrate epithelial cells and directly modulate intracellular inflammatory signaling makes it a candidate for local anti-inflammatory activity in the gastrointestinal tract.[3][4]

Evidence Summary

In Vitro Studies

Brzoska et al. demonstrated that KPV and other alpha-MSH C-terminal tripeptides inhibit NF-kB nuclear translocation in human keratinocytes and dermal fibroblasts stimulated with IL-1β. The anti-inflammatory effect was dose-dependent and occurred at micromolar concentrations. Critically, this effect was independent of melanocortin receptor binding, as demonstrated by the absence of cAMP elevation and the inability of melanocortin receptor antagonists to block the effect.[1]

Luger et al. provided comprehensive reviews of alpha-MSH-derived peptides including KPV, documenting their anti-inflammatory effects across multiple cell types including macrophages, dendritic cells, and epithelial cells. The reduction in pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6, IL-8) was consistently demonstrated across studies.[2]

Animal Studies

Kannengiesser et al. demonstrated that KPV, delivered in nanoparticle formulations, reduced inflammation in murine models of colitis (DSS-induced and TNBS-induced). Treated animals showed reduced histological damage scores, decreased inflammatory cell infiltration, and lower pro-inflammatory cytokine levels in colonic tissue.[4]

Moustafa et al. explored the delivery of KPV-loaded nanoparticles specifically targeting inflamed colonic tissue and demonstrated that targeted delivery enhanced the therapeutic efficacy of KPV in experimental colitis models, achieving mucosal healing and reduced disease activity indices.[3]

Human Evidence

No published human clinical trials of KPV for any indication exist. Anecdotal reports from self-experimenters, particularly in IBD and IBS communities, describe subjective improvements in gastrointestinal symptoms with oral and subcutaneous KPV use, but these cannot be considered reliable evidence. The absence of controlled human data means that the therapeutic index, optimal dosing, and true adverse event profile of KPV in humans are entirely unknown.

Primary Uses (in Research)

Based on the available preclinical literature, KPV has been investigated for the following applications:

• Gut inflammation (IBD/IBS) — The primary area of interest. Animal models demonstrate mucosal healing and reduced intestinal inflammation, with potential applications in Crohn's disease and ulcerative colitis.[3][4]
• General anti-inflammatory effects — Broad suppression of NF-kB-mediated inflammation, with potential applications across inflammatory conditions affecting skin, joints, and other tissues.[1][2]
• Skin inflammation — Topical application for inflammatory dermatological conditions, leveraging the anti-inflammatory effects demonstrated in keratinocyte and fibroblast models.[1]
• Wound healing — Modulation of the inflammatory phase of wound healing, potentially accelerating the transition from inflammation to proliferation and remodeling.[2]

Contraindications

Standard Protocols

Common Stacks & Synergies

In the peptide research and self-experimentation community, KPV is sometimes combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined use:

• KPV + BPC-157 (oral) — The most commonly discussed combination for gut health. The rationale is that KPV provides direct anti-inflammatory action via NF-kB inhibition while BPC-157 promotes mucosal healing through growth factor and angiogenic pathways. Both peptides are used orally for GI applications.
• KPV + LL-37 — The rationale combines KPV's anti-inflammatory effects with LL-37's antimicrobial and anti-biofilm properties, targeting both inflammation and potential infectious contributors to GI symptoms.
• KPV + Larazotide — Larazotide (a tight junction regulator) is sometimes discussed alongside KPV for individuals with intestinal permeability concerns. KPV addresses the inflammatory component while larazotide targets tight junction integrity.

Preparation & Administration

KPV is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 5 mg or 10 mg of peptide. For injection use, it must be reconstituted with bacteriostatic water (BAC water). KPV is also available in oral capsule formulations from compounding pharmacies.

Reconstitution (for SubQ use)

For a standard 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 200 mcg. Adjust reconstitution volume to achieve desired concentration. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. For systemic anti-inflammatory effects, typical injection sites include the abdominal area. For localized GI effects, some practitioners inject in the abdominal region near the GI tract, though the pharmacokinetic rationale for this approach is unvalidated. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Oral Administration

KPV is a tripeptide (only 3 amino acids), which raises the possibility that it may survive gastric acid and intestinal protease degradation better than larger peptides, potentially reaching the intestinal mucosa intact. However, the oral bioavailability of KPV has not been rigorously characterized. Oral capsules are typically taken on an empty stomach. Some compounding formulations use enteric coatings or nanoparticle delivery systems to enhance intestinal delivery.[3]

Side Effects & Adverse Events

In preclinical studies, KPV has shown a favorable tolerability profile with no significant toxicity reported at the doses tested in animal models of colitis.[3][4]

Self-reported side effects from community use (unverified):

• Injection site redness, swelling, or mild pain (most commonly reported for SubQ use)
• GI changes including altered stool consistency, bloating, or mild nausea (reported with oral use, may be related to the peptide's effects on intestinal inflammation)
• Fatigue (infrequent, self-reported)
• Headache (rare, self-reported)

The most significant theoretical safety concern is the potential for long-term immunosuppression with chronic NF-kB inhibition. NF-kB is essential for normal immune function, and sustained suppression could impair host defense against infections and reduce immune surveillance against malignancy. This risk has not been evaluated in long-term studies of KPV.

Drug Interactions

No formal drug interaction studies have been conducted with KPV in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Immunosuppressants (cyclosporine, tacrolimus, methotrexate, biologics) — KPV's anti-inflammatory effects via NF-kB inhibition could theoretically be additive with immunosuppressive medications, increasing the risk of excessive immunosuppression and opportunistic infection.
• TNF-alpha inhibitors (adalimumab, infliximab, etanercept) — KPV reduces TNF-alpha production through NF-kB suppression. Concurrent use with TNF inhibitors could produce additive or excessive TNF suppression.
• Corticosteroids — Both corticosteroids and KPV suppress NF-kB-mediated inflammation through different mechanisms. Additive anti-inflammatory (and immunosuppressive) effects are theoretically possible.
• NSAIDs — KPV and NSAIDs target overlapping inflammatory pathways. Concurrent use may produce additive anti-inflammatory effects, which could be beneficial for symptom control but may also increase immunosuppressive risk.
• Melanocortin receptor agonists (e.g., PT-141, melanotan) — While KPV does not itself activate melanocortin receptors, concurrent use with other alpha-MSH-derived peptides that do activate these receptors could produce complex immunomodulatory interactions.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold as a research chemical. Some compounding pharmacies prepare KPV formulations (oral capsules, topical creams) for prescriber-ordered use.
• EMA (European Union) — Not approved as a medicinal product. Available as a research chemical.
• WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026.
• Australia (TGA) — Not approved. Likely classified as a prescription-only substance under the Poisons Standard.
• Not scheduled — KPV is not classified as a controlled substance in any major jurisdiction. It is legal to purchase for research purposes but not legal to market for human therapeutic use.

Open Questions

Significant gaps remain in the KPV evidence base. Key unresolved questions include:

• Oral bioavailability — Whether the tripeptide KPV survives gastrointestinal degradation and reaches the intestinal mucosa at therapeutic concentrations is a fundamental open question. As a very small peptide (3 amino acids), it may be more resistant to protease degradation than larger peptides, but rigorous pharmacokinetic data is lacking.
• Optimal route of administration — Whether subcutaneous, oral, or topical administration is most effective for specific indications (gut inflammation, skin inflammation, systemic inflammation) has not been determined.
• Clinical efficacy for IBD — Despite promising animal model data, no human clinical trials have been conducted for Crohn's disease, ulcerative colitis, or any other IBD indication. The translation from murine colitis models to human IBD is uncertain.
• Long-term immunosuppressive risk — Chronic NF-kB inhibition raises theoretical concerns about impaired host defense against infections and reduced immune surveillance against malignancy. No long-term safety studies have addressed this question.
• Dose-response relationship — Optimal dosing in humans has not been established for any route or indication.
• Purity and quality control — As an unregulated research chemical, the purity, sterility, and accurate labeling of commercially available KPV products cannot be guaranteed.

Bibliography

1. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocr Rev. 2008;29(5):581-602. doi:10.1210/er.2007-0027. PMID:18612139.
2. Luger TA, Brzoska T. "Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Ann Rheum Dis. 2007;66 Suppl 3:iii52-5. doi:10.1136/ard.2007.079780. PMID:17934097.
3. Moustafa M, Bhatt N, Li J, Lin PH. "Oral delivery of KPV-loaded alginate/chitosan nanoparticles targeting intestinal inflammation." FASEB J. 2015;29(1 Suppl):921.6.
4. Kannengiesser K, Maaser C, Heidemann J, Luger TA, Brzoska T, Kucharzik T. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis. 2008;14(3):324-31. doi:10.1002/ibd.20334. PMID:18092347.